Market analysis reveals that the off-label prescribing boom generated billions in additional revenue for manufacturer Novo Nordisk, even as reports of serious adverse events began accumulating and lawsuits claim the company prioritized profits over patient safety
According to the recently reported results of a phase 2 trial in patients with gastrointestinal stromal tumors, linsitinib achieved no objective responses in these patients, although the rate of 9-month clinical benefit, progression-free survival, and overall survival at 9 months was 40%, 52% and 80%, respectively [162]
This affects sourcing, cost, and quality assurance considerations
Patient Experiences with LifeRx.md LifeRx.md has garnered numerous positive reviews from patients who have embarked on their weight loss journey with the assistance of GLP-1 agonists
Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real-world setting: A 6-month retrospective study in the United States (SCOPE)
